Omniscient Neurotechnology develops AI-driven brain analysis tools that apply connectomics to map and interpret individual brain networks. Its flagship Quicktome platform provides insights across a range of neurologic conditions, including cranial surgery, neuro-oncology, stroke, and mental illness. The company says its technology supports personalized brain medicine aimed at transforming care for Alzheimer’s, Parkinson’s, depression, and other disorders. Omniscient plans to expand commercially and pursue new clinical applications, with stated ambitions to enter markets such as brain-computer interfaces, stroke, and movement disorders. The company is led by CEO Stephen Scheeler and has attracted long-term investor support through multiple funding rounds. No operating metrics were provided in the article.

Total raised

$57M

Funding rounds

3

Latest round

Series D

Latest activity

Jun 2026